专利检索 ap:("ASCENTAGE PHARMA (SUZHOU) CO., LTD." OR "THE REGENTS OF THE UNIVERSITY OF MICHIGAN" OR "ASCENTAGE PHARMA GROUP CORP LIMITED") AND inv:"Dongbo Li" 第 1 页

1.

发明申请
MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS 有权

公开(公告)号：US20220396587A1

公开(公告)日：2022-12-15

申请号：US17048688

申请日：2020-01-22

申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED

发明人： Guozhi Tang , Dongbo Li , Liugen Li , Xianchan Zha , Wenming Chen , Shaomeng Wang , Chao-Yie Yang

IPC分类号： C07D515/22 , C07D497/22 , A61P35/00

摘要： Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

2.

发明授权
Macrocyclic indoles as Mcl-1 inhibitors 有权

公开(公告)号：US11691989B2

公开(公告)日：2023-07-04

申请号：US17047423

申请日：2019-11-20

申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED

发明人： Hao Chen , Wenming Chen , Chao Li , Dongbo Li , Yu Jing , Guozhi Tang , Yunlong Zhou , Shaomeng Wang , Chao-Yie Yang

IPC分类号： C07D497/22 , C07D515/22 , C07D231/12 , A61K31/395 , A61P35/00

CPC分类号： C07D515/22 , A61P35/00

摘要： Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

3.

发明申请
MACROCYCLIC INDOLES AS MCL-1 INHIBITORS 有权

公开(公告)号：US20220340595A1

公开(公告)日：2022-10-27

申请号：US17047423

申请日：2019-11-20

申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED

发明人： Hao Chen , Wenming Chen , Chao Li , Dongbo Li , Yu Jing , Guozhi Tang , Yunlong Zhou , Shaomeng Wang , Chao-Yie Yang

IPC分类号： C07D515/22 , A61P35/00

摘要： Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.